Turn it on to take full advantage of this site, then refresh the page.
Search our people now:
Life Sciences partner Stephen Paul Mahinka comments on the FTC v. Cephalon, the FTC's challenge on pay-for-delay agreements restricting generic drug market entry.
Copyright © 2021 Morgan, Lewis & Bockius LLP. All rights reserved.